한국어
Quantus

aTyr Pharma

LIFE · Nasdaq
$39.85+5.67%
2026-09-04 close

aTyr Pharma last closed at $39.85 (+5.67%) on 2026-09-04. Signals today: MA aligned. Listed on Nasdaq; price, financials and dividends update daily after market close.

Loading chart…
CloseMA20MA60MA120

New high + volume — the real recordrecord · not a prediction

Last 30 sessions
277 picks
Next-day win rate
44.2%
Avg next-day
-0.28%
vs market
-0.51%p

Every new-high-plus-volume pick we actually published (US market) — not this stock alone.

Trade plan

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

Past reported results · not investment advice

More — deeper indicators

Financial safety

Reference indicatorAs of 2012
Grey zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 2.58
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
2.58
Beneish M-Score
-2.55

No statistical flag

Sloan accrual
-4.02%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

8/9Strong

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score8/9

Profitability

  • Positive ROAPass
  • Positive OCFPass
  • Improving ΔROAPass
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtPass
  • Higher current ratioNot passed
  • No new sharesPass

Efficiency

  • Higher gross marginPass
  • Higher asset turnoverPass

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Cash conversion cycleWarning

현금전환주기(CCC) 3기 연속 확대 — 운전자본 경색·현금 회수 지연 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
17.5%
Interest coverage
5.4x
Return on equity (ROE)
9.3%

Operating margin −5pp

Tolerable
Interest coverageBase 5.4x adverse case 3.8x
Return on equity (ROE)Base 9.3% adverse case 7.6%

Revenue −15%

Tolerable
Interest coverageBase 5.4x adverse case 4.6x
Return on equity (ROE)Base 9.3% adverse case 9.5%

Interest rate +2pp

Tolerable
Interest coverageBase 5.4x adverse case 3.3x
Return on equity (ROE)Base 9.3% adverse case 9.9%

Interest coverage limit

Current margin 14.3pp

Interest coverage limit at an operating margin of 3.3%

Interest expense coverage threshold

Connections

AI-extracted related companies · for reference

Customers
Eli Lilly
🔗 See in the full market map →

Recent filings

Filings for overseas stocks are on the way. For now we cover Korean stocks only.

About aTyr Pharma
What technical signals does aTyr Pharma (LIFE) have?
aTyr Pharma current technical signals: MA alignment (score 0.99).
Is aTyr Pharma a cup-and-handle pattern?
No. aTyr Pharma has no valid cup-and-handle signal right now.
What are aTyr Pharma's financials and valuation?
aTyr Pharma's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy